RESUMO
When administered as a single agent to rats, the previously reported calcium receptor antagonist 3 elicited a sustained elevation of plasma PTH resulting in no increase in overall bone mineral density. The lack of a bone building effect for analogue 3 was attributed to the large volume of distribution (V(dss)(rat) = 11 L/kg), producing a protracted plasma PTH profile. Incorporation of a carboxylic acid functionality into the amino alcohol template led to the identification of 12 with a lower volume of distribution (V(dss)(12) = 1.18 L/kg) and a shorter half-life. The zwitterionic nature of antagonist 12 necessitated the utility of an ester prodrug approach to increase overall permeability. Antagonist 12 elicited a rapid and transient increase in circulating levels of PTH following oral dosing of the ester prodrug 11 in the dog. The magnitude and duration of the increases in plasma levels of PTH would be expected to stimulate new bone formation.
Assuntos
Amino Álcoois/síntese química , Hormônio Paratireóideo/sangue , Fenilpropionatos/síntese química , Pró-Fármacos/síntese química , Propanolaminas/síntese química , Receptores de Detecção de Cálcio/antagonistas & inibidores , Administração Oral , Amino Álcoois/farmacocinética , Amino Álcoois/farmacologia , Animais , Disponibilidade Biológica , Cálcio/metabolismo , Linhagem Celular , Citoplasma/metabolismo , Cães , Ésteres , Humanos , Hormônio Paratireóideo/metabolismo , Permeabilidade , Fenilpropionatos/farmacocinética , Fenilpropionatos/farmacologia , Pró-Fármacos/farmacocinética , Pró-Fármacos/farmacologia , Propanolaminas/farmacocinética , Propanolaminas/farmacologia , Ensaio Radioligante , Ratos , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Functional screening of the former SmithKline Beecham compound collection against the human calcium receptor (CaR) resulted in the identification of the amino alcohol-based hit 2 (IC(50) = 11 microM). Structure-activity studies of 2 focused on the optimization of the right- and left-hand side aromatic moieties as well as the amino alcohol linker region. Critical to the optimization of this antagonist template was the discovery that the chirality of the C-2 secondary alcohol played a key role in enhancing both CaR potency as well as selectivity over the beta-adrenergic receptor subtypes. These SAR studies ultimately led to the identification of 38 (NPS 2143; SB-262470A), a potent and orally active CaR antagonist. Pharmacokinetic characterization of 38 in the rat revealed that this molecule had a large volume of distribution (11 L/kg), which resulted in a prolonged systemic exposure, protracted increases in the plasma levels of PTH, and an overall lack of net bone formation effect in a rodent model of osteoporosis.
